Managing Principal
Licensed in the State of Michigan (1998), District of Columbia (2002), and province of Ontario (2010)
Harvard Law School (Negotiations, 2017), Boston University School of Law (LL.M. Financial Laws, 1999), and Michigan State University Law (JD, 1997)
Office: Detroit
Mobile Phone: (248) 787-6078
Email: amorganti@morgantico.com
Between 1999 and 2009, Andrew litigated antitrust and shareholder claims in the United States U.S. federal and various state courts. During 2010, he transferred his practice to Ontario, Canada, to emphasis representing clients located around the globe in North American courts. Andrew has handled virtually all aspects of the plaintiff-side litigation and has argued motions in various state courts, U.S. Federal District Court for the Southern District of New York, Northern and Central Districts of California, the Ontario Superior Court of Justice and Ontario Court of Appeal.
The more notable cases that Andrew has litigated include: Kauf v. Colt Resources, Inc., 2019 ONSC 2179 (The resignation of a C-level employee can serve as a misrepresentation for failing to disclose why C-level was discharged by the Board); Paniccia v. MDC Partners, Inc., 2017 ONSC 7298 (Choice of Law); Kaynes v. BP, PLC, 2017 ONSC 5172 (Limitation Period); Wong v. Pretium Resources, Inc., 2017 ONSC 3361 (Leave to Proceed with Statutory Shareholder Claim), appeal denied; Kaynes v. BP, PLC, 2013 ONSC 5802 (Subject Matter Jurisdiction the antithesis of Morrison v. NAB, 561 U.S. 247 (2010)); In re Dairy Antitrust Litigation, MDL No. 2031 (Originated theory that resulted in the U.S. CFTC Docket No. 09-02); In re Initial Public Offering Securities Litigation, 21 MC 92 (SAS)(S.D.N.Y.); Myers v. Merrill Lynch & Co., Inc., et al., BC312115 (L.A. Sup. Crt.)(Successfully defeating defendants’ demurrer relating to fraudulent analyst research reports); and In re Cardizem CD Antitrust Litigation, MDL No. 1278 (E.D. Mich.)(Member of the plaintiff team that was successful in obtaining summary judgment against the defendants pharmaceutical companies’ reverse payment illegal agreement to restrict competition between branded and generic products).
Andrew has been a guest lecturer of over a dozen conferences, including for the American Bar Association, University of Michigan Law, Ontario Bar Association, Offshore Alert (the Journal), and has been published in per review journals, see, Ellen Meriweather and Andrew Morganti, Emerging Trends in Certification of Antitrust Class Actions in Canada, ABA Antitrust, Vol. 24, No. 3, Summer 2010.
Andrew previously practiced law at the firms of Milberg Weiss Bershad & Schulman, LLP (New York, New York), Finkelstein Thompson & Loughran, LLP (Washington, District of Columbia), and Miller Faucher Cafferty and Wexler, LLP (Ann Arbor, Michigan).